alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 73, Number 85 (Thursday, May 1, 2008)]
[Notices]
[Pages 24040-24041]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-1207]


=======================================================================
-----------------------------------------------------------------------

COMMISSION ON CIVIL RIGHTS


Sunshine Act Notice

Agency: United States Commission on Civil Rights.

Action: Notice of meeting.

Date and Time: Friday, May 9, 9:30 a.m.

Place: U.S. Commission on Civil Rights, 624 Ninth Street, NW., Rm. 540, 
Washington, DC 20425.

Meeting Agenda

I. Approval of Agenda
II. Approval of Minutes
    <bullet> March 7, 2008 Meeting
III. Announcements
IV. Staff Director's Report
V. Management and Operations
    <bullet> Status of FY 2009 Budget

[[Page 24041]]

Submission
VI. Program Planning
    <bullet> Proposed Change to 2008 Briefing Schedule
    <bullet> 2010 Program Planning Proposals
    <bullet> Briefing Report on Voter Fraud and Voter Intimidation
    <bullet> Briefing Report on Racial Categorization in the Census
    <bullet> Briefing Report on the Educational Effectiveness of 
Historically Black Colleges and Universities
VII. State Advisory Committee Issues
    <bullet> Florida SAC
    <bullet> Kentucky SAC
    <bullet> Wyoming SAC
    <bullet> Appointment to Texas SAC
VIII. Future Agenda Items
IX. Adjourn

For Further Information Contact: Lenore Ostrowsky, Acting Chief, Public 
Affairs Unit (202) 376-8582.

    Dated: April 29, 2008.
David Blackwood,
General Counsel.
[FR Doc. 08-1207 Filed 4-29-08; 1:57pm]
BILLING CODE 6335-01-P
# C_2011023EN.01000502.xml

| 25.1.2011 | EN | Official Journal of the European Union | C 23/5 |
| --- | --- | --- | --- |

25.1.2011

EN

Official Journal of the European Union

C 23/5

---

Non-opposition to a notified concentration

(Case COMP/M.6084 — Wittington/Divisie Bijenkorf)

(Text with EEA relevance)

2011/C 23/03

On 19 January 2011, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32011M6084. EUR-Lex is the on-line access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32011M6084. EUR-Lex is the on-line access to the European law.

---
* Pursuant to 5 TH C IR

. R. 47.5, the court has determined that this opinion should not be

published and is not precedent except under the limited circumstances set forth in 5 TH C IR

. R. 47.5.4. IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 98-41063

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

RAFAEL MIRANDA,

DefendantAppellant.

------------------------------------------------------- Appeals from the United States District Court

for the Southern District of Texas

USDC No. M-97-CR-379-5

June 8, 2000

Before HIGGINBOTHAM, DeMOSS and STEWART, Circuit Judges.

PER CURIAM: *

Rafael Miranda appeals his jury conviction for conspiracy to possess with intent to distribute

marijuana. He argues that the evidence was insufficient to support his conspiracy conviction. When

a defendant fails to renew his motion for a judgment of acquittal at the close of all the evidence,

review is limited to plain error. U nited States v. McCarty

, 36 F.3d 1349, 1358 (5th Cir. 1994).

Miranda has not shown t hat “t he record is devoid of evidence pointing to guilt, or . . . [that] the

evidence on a key element of the offense was so tenuous t hat a convict ion would be shocking.’”

United States v. Parker

, 133 F.3d 322, 328 (5th Cir. 1998)(quoting United States v. Pierre

, 958 F.2d

1304, 1310 (5th Cir. 1992) (en banc)).Miranda also argues t hat the district court erred in determining that he was a leader or

organizer under § 3B1.1(a) of the United States Sentencing Guidelines. The evidence presented at

the trial and the facts in the PSR indicate that Miranda participated in every phase of the conspiracy:

he negotiated the agreement to transport the marijuana from McAllen to Tampa; he was present when

the marijuana was delivered to the confidential informants for transportation at the K-Mart parking

lot; the marijuana was delivered in a van registered to Miranda; he drove to the stash house after the

delivery in the K-Mart parking lot; and he was present at the controlled delivery in Tampa and handed

a bag contained $44,980 to the confidential info rmant . The conspiracy involved five or more

participants, including Miranda, Claudia Hernandez, Anto nio Hernandez, Gonzalez-Rios, Israel

Gomez, and Israel Rivera. Therefore, Miranda has not shown that the district court erred determining

that he was a leader or organizer in the offense. S ee United States v. Ismoila

, 100 F.3d 380, 395 (5th

Cir. 1996).

AFFIRMED.
Exhibit 32.1  CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  In connection with the Quarterly Report of Adtomize Inc. (the Company) on Form 10-Q for the period ended September 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.   Date:   November 15, 2010   /s/ Barry Wattenberg --------------------------------- Barry Wattenberg, Principal Executive Officer and Principal Accounting Officer
Exhibit
32.1








CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of AVT, Inc., a Nevada corporation, (the
“Company”) on Form 10-Q for the period ended June 30, 2008, as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), I, Natalie
Russell, President and acting Chief Financial Officer of the Company, certify
the following pursuant to Section 18, U.S.C. 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002:





1.
            The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





2.
            The
      information contained in the report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.








/s/ Natalie
Russell


President


Acting
Chief Financial Officer





August
19, 2008
Table of Contents


Exhibit 13.1 CERTIFICATION 
Pursuant to 18 United States Code Section 1350, 
As adopted pursuant to Section 906 of the 
Sarbanes-Oxley Act of 2002 The undersigned hereby certifies that, to such officers knowledge, the Annual Report on Form 20-F for the period ended December 31, 2009 of Net Serviços de Comunicação S.A. (the Company) filed with the Securities and Exchange Commission on the date hereof fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such annual report fairly presents, in all material respects, the financial condition and results of operations of the Company. /s/José Antonio Guaraldi FélixName:
     José Antonio Guaraldi FélixTitle:
     Chief Executive OfficerDate:
     May 20th, 2010


---
AGENDA 

Advisory Board on Radiation and Worker Health 

Meeting of the 

Subcommittee on Dose Reconstruction Review 

June 6, 2012 

Cincinnati Airport Marriott
 

2395 Progress Dr. 

Hebron, KY 41048
 

859-586-0166
 

Conference Call Number: 1-866-659-0537
 

Participant Pass Code: 9933701
 

9:00 a.m. Eastern Time 

Welcome and roll-call 

Discussion 

 Update on DCAS “blind DR” quality control evaluations
 

 Overview of ORAU quality management system 

 Items related to NIOSH 10-year review 

- DCAS report on resource implications of possible changes in dose 

reconstruction efficiency processes 

- DCAS report on plans for evaluating claimant favorability 

 Issue resolution for cases with Category A findings for sets 10-13 

 Continuation of issue resolution for set 8 

 Accelerating DR issue resolution process 

 Preparing DR case set 16 cases for preliminary selection 

 Preparing second Board report to the Secretary on dose reconstruction reviews 

5:00 pm Adjourn
**EXHIBIT 23.1**

 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

 

To the Board of Directors and Stockholders 

Factory Card & Party Outlet Corp. and Subsidiary 

Naperville, Illinois 

 

We have issued our report, dated April 19, 2007, on the consolidated financial statements of Factory Card & Party Outlet Corp. and Subsidiary which are includedin the annual report of Factory Card & Party Outlet Corp. and Subsidiary on Form 10-K for the year ended February 3, 2007. We hereby consent to the incorporation by reference of our report in the Registration Statements of FactoryCard & Party Outlet Corp. and Subsidiary on Form S-8 (No. 333-92248, No. 333-98549 and No. 333-108222). 

 

/s/ MCGLADREY & PULLEN LLP 

Schaumburg, Illinois 

April 19, 2007
AGENDA

Advisory Board on Radiation and Worker Health

Pacific Proving Grounds Work Group

Teleconference Meeting

January 16, 2015

Conference Call Number: 1-866-659-0537 Participant Pass Code: 9933701

1:30 p.m. Eastern Time

Welcome and Introductions

Discussion:

• Overview of SC&A Site Profile Review

• Findings resolution

• Actions/path forward

Adjourn
SUFFICIENT ACCURACY

Jim Melius, Jim Neton
REGULATION

– Per 42 CFR § 83.13 (c)(1)(i), Radiation do

reconstructed with sufficient accuracy if Nestablished that it has access to sufficient to estimate the maximum radiation dose, ftype of cancer for which radiation doses areconstructed, that could have been incurrplausible circumstances by any member of or if NIOSH has established that it has accsufficient information to estimate the radiaof members of the class more precisely thaestimate of the maximum radiation dose. 


PRELIMINARY STEPS

REVIEW WORK PROCESS – SOURC

POTENTIAL TYPES OF EXPOSURE

IDENTIFY EXPOSED POPULATION

WAS EXPOSED, VARIABILITY 

APPLY HIERARCHICAL REVIEW T

EXPOSED POPULATION(S) 
PERSONAL MONITORING DA

DEMONSTRATE THAT HIGHEST E

WORKERS WERE COVERED 

EVERYONE MONITORED OR MON

GROUP INCLUDED HIGHEST EXPO

MONITORING METHOD MUST BE COWORKER MODELS MUST BE 

INCLUSIVE AND ACCOUNT FOR STRATIFICATION 
OTHER DATA

AIR MONITORING, SOURCE TERM

SURROGATE DATA ARE MORE PROBLEMATIC 

NEED TO SHOW THAT MONITORIN

MODEL ACCOUNTS FOR THE HIGHEXPOSED BUT IS PLAUSIBLE (E.GUNREALISTICALLY HIGH) 
CONSIDERATION OF EXPOSU

POTENTIAL

HOW MUCH ACCURACY IS SUFFICFOR LOW EXPOSURE POTENTIAL 

ACCURACY SUFFICIENT? 

EXAMPLE – RESIDUAL PERIOD. PROBLEM WITH EVALUATING 

COWORKER MODELS FOR STRATIFICATION
I 

115TH CONGRESS 

2D SESSION H. R. 5483 

To impose a deadline for the promulgation of interim final regulations in 

accordance with section 311(h) of the Controlled Substances Act (21 

U.S.C. 831(h)) specifying the circumstances in which a special registration may be issued to a practitioner to engage in the practice of telemedicine, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 12, 2018 

Mr. CARTER of Georgia (for himself, Mrs. BUSTOS, Ms. STEFANIK, Mrs. HANDEL, Ms. KUSTER of New Hampshire, and Mr. RUSH) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period 

to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee 

concerned 

A BILL 

To impose a deadline for the promulgation of interim final 

regulations in accordance with section 311(h) of the Controlled Substances Act (21 U.S.C. 831(h)) specifying the 

circumstances in which a special registration may be 

issued to a practitioner to engage in the practice of 

telemedicine, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


lotter on DSKBCFDHB2PROD with BILLS
2 

•HR 5483 IH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Special Registration 

3 for Telemedicine Clarification Act of 2018’’. 

4 SEC. 2. DEADLINE FOR INTERIM FINAL REGULATIONS FOR 

5 A SPECIAL REGISTRATION TO ENGAGE IN 

6 THE PRACTICE OF TELEMEDICINE. 

7 Section 311(h)(2) of the Controlled Substances Act 

8 (21 U.S.C. 831(h)(2)) is amended by striking ‘‘The Attor9 ney General shall, with the concurrence of the Secretary, 

10 promulgate regulations’’ and inserting ‘‘Not later than 90 

11 days after the date of enactment of the Special Registra12 tion for Telemedicine Clarification Act of 2018, the Attor13 ney General shall, with the concurrence of the Secretary, 

14 promulgate interim final regulations’’. 

Æ 


lotter on DSKBCFDHB2PROD with BILLS
<PAGE>   1


                                                                   Exhibit 10.31

   SCHEDULE TO FORM OF NHP SECOND SERIES WORKING CAPITAL ASSURANCE AGREEMENT
        FILED PURSUANT TO INSTRUCTION 2 TO ITEM 601(a) OF REGULATION S-K

<TABLE>
<CAPTION>
------------------------------ ---------------------- ---------------- --------------- --------------------- ----------------------
Facility Location              Lessee                 County           State           Loan Amount           Manager
------------------------------ ---------------------- ---------------- --------------- --------------------- ----------------------
<S>                           <C>                    <C>              <C>             <C>                   <C>
Pensacola, FL                  C&G Healthcare of      Escambia         Florida         $179,700              Balanced Care at
                               Pensacola, LLC                                                                Pensacola, Inc.
------------------------------ ---------------------- ---------------- --------------- --------------------- ----------------------
Tallahassee, FL                C&G Healthcare of      Leon             Florida         $223,350              Balanced Care at
                               Tallahassee, LLC                                                              Tallahassee, Inc.
------------------------------ ---------------------- ---------------- --------------- --------------------- ----------------------
Hagerstown, MD                 C&G Healthcare at      Washington       Maryland        $124,350.00           Balanced Care at
                               Hagerstown, LLC                                                               Hagerstown, Inc.
------------------------------ ---------------------- ---------------- --------------- --------------------- ----------------------
Johnson City,                  C&G Healthcare at      Washington       Tennessee       $138,900.00           Balanced Care at
TN                             Johnson City, LLC                                                             Johnson City, Inc.
------------------------------ ---------------------- ---------------- --------------- --------------------- ----------------------
Teay's Valley,                 C&G Healthcare at      Putnam           West Virginia   $122,100.00           Balanced Care at
WV                             Teay's Valley, LLC                                                            Teay's Valley, Inc.
------------------------------ ---------------------- ---------------- --------------- --------------------- ----------------------
</TABLE>
EXHIBIT 31.1













Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002


------------------------------------------------------------------------




We, Steven Schneider and Alex Wang, certify that:




1.           We have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of ZAP; and




2.           Based on our knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.









Date:  April 29, 2011                                                                           By: /s/ Steven Schneider


Steven Schneider, Co-Principal Executive Officer







Date:  April 29, 2011                                                                           By: /s/ Alex Wang


Alex Wang, Co-Principal Executive Officer
Miller, Diane M.

—_
From:

Sent: Thursday, August 01, 2002 2:04 PM

To: niocindocket@cdc.gov

Subject: Private Citizen Comments For The Public Docket for 42 CFR 83 (Spe cial Exposure Cohort)

Please except these comments to be included in the Public Docket for 42 CFR
83 (Special Exposure Cohort).

*“* The process to include a facility in the Special Exposure Cohort is far

too slow. No new facilities will be added to the SEC until after the

procedures are finalized which | am told by NIOSH will likely be in early

2003. Congress requires 180 days to review a recommendation to add a
facility. NIOSH must determine that dose reconstructions can not be done
for a class of employees at a particular facility before being considered

for addition to the SEC. | am told by NIOSH that the time required to
determine that dose reconstructions can not be done is unknown. It seems to
me that it will be years before anyone with a legitimate claim will collect
EEOICPA compensation via this path.

** My father worked at Linde in Tonawanda, NY from 1941 until 1978 when he
was diagnosed with cancer. At 59 years old, he succumbed to the cancer
seven months after diagnosis. If he was still alive but given the same
diagnosis today, he would not survive long enough to get compensation under
this Law.

** My father's coworkers have said to me that, with the exception of some
X-ray technicians, the factory workers at Linde did not wear any kind of
personal radiation monitoring devices. This will make dose reconstructions
very difficult if not impossible for the Linde employees. | anticipate that

the Linde employees will ultimately have to petition to be added to the SEC
and they will then be subjected to the delays designed into this process.
Many eligible workers will not survive long enough to collect compensation
because of these delays.

** Those facilities that are already in the SEC were given their SEC status
based on certain criteria. Some of those criteria being the likelihood that
radiation caused the higher than normal incidence of radiation related
illnesses and the absence of adequate radiation monitoring for use in dose
reconstructions. Linde and many other facilities meet those criteria. Why
were they not included in the SEC from the beginning?

** The claimants should at least be able to get an reasonable estimate as
to when their claims will be processed. It is difficult to make future
plans without knowing claim status.

As the procedures are finalized, please consider these comments and strive
for a process that is efficient, fair, and swift.

Regards,
AGENDA

Advisory Board on Radiation and Worker Health 

Meeting of the

Idaho National Laboratory Work Group

March 25, 2014

Cincinnati Airport Marriott

2395 Progress Dr. 

Hebron, KY 41048

859-586-0166

Conference Call Number: 1-866-659-0537

Participant Pass Code: 9933701

9:00 a.m. Eastern Time Welcome and roll-call/introductions

Discussion

• Status of WG review

• Issues recommended for closure

• NIOSH/SC&A matrices

• NIOSH responses (white papers) on Issues 1, 2, 19, 24, 34

• Deliverables

• Future meeting plans

Adjourn
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - 21 CFR Part 1271

### CFR Correction

In Title 21 of the Code of Federal Regulations, Parts 800 to 1299, revised as of April 1, 2007, in part 1271, on page 718, § 1271.22 is reinstated to read as follows:

§ 1271.22

(a) You must use Form FDA 3356 for:

(1) Establishment registration,

(2) HCT/P listings, and

(3) Updates of registration and HCT/P listing.

(b) You may obtain Form FDA 3356:

(1) By writing to the Center for Biologics Evaluation and Research (HFM-775), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, Attention: Tissue Establishment Registration Coordinator;

(2) By contacting any Food and Drug Administration district office;

(3) By calling the CBER Voice Information System at 1-800-835-4709 or 301-827-1800; or

                        (4) By connecting to                         *http://www.fda.gov/​opacom/​morechoices/​fdaforms/​cber.html*                         on the Internet.                    

(c)(1) You may submit Form FDA 3356 to the Center for Biologics Evaluation and Research (HFM-775), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, Attention: Tissue Establishment Registration Coordinator; or

                        (2) You may submit Form FDA 3356 electronically through a secure web server at                         *http://www.fda.gov/​cber/​tissue/​tisreg.htm*.                    
69 FR 68681

[FR Doc. 08-55500 Filed 1-17-08; 8:45 am]

BILLING CODE 1505-01-D
AGENDA 

Advisory Board on Radiation and Worker Health 

TBD 6000 Work Group 

February 4, 2020 Teleconference 

Conference Call Number: 866-659-0537 

Participant Pass Code: 9933701 

Superior Steel Co. SEC Petition (1952-1957) 

1:00 p.m. Eastern Time 

1. Welcome and roll-call/introductions .......................................... Ted Katz, DFO 

2. Review of the NIOSH responses for the Superior Steel Co. Special Exposure Cohort 

(SEC-00247) Issues Matrix 

3. Petitioner Comments/Questions (optional) 

4. Work Group discussion, actions 

5. Path forward 

Adjourn